{
    "organizations": [],
    "uuid": "1bfcb2a62135e79464ca24c4b65a83b63995fd2b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-synergy-pharmaceuticals-announces/brief-synergy-pharmaceuticals-announces-fda-approval-of-trulance-idUSASB0C29T",
    "ord_in_thread": 0,
    "title": "BRIEF-Synergy Pharmaceuticals Announces FDA Approval Of TRULANCE",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 25 (Reuters) - Synergy Pharmaceuticals Inc:\n* SYNERGY PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF TRULANCE® (PLECANATIDE) FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN ADULTS\n* SYNERGY PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF TRULANCE® (PLECANATIDE) FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN ADULTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-25T19:10:00.000+02:00",
    "crawled": "2018-01-26T21:13:49.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "synergy",
        "pharmaceutical",
        "inc",
        "synergy",
        "pharmaceutical",
        "announces",
        "fda",
        "approval",
        "plecanatide",
        "treatment",
        "irritable",
        "bowel",
        "syndrome",
        "constipation",
        "adult",
        "synergy",
        "pharmaceutical",
        "announces",
        "fda",
        "approval",
        "plecanatide",
        "treatment",
        "irritable",
        "bowel",
        "syndrome",
        "constipation",
        "adult",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}